MARK WILSON

Allergan Aesthetics is one of the biggest names in the industry. What would you attribute that success to?

For me, the key has been building a deep understanding of practitioners and their patients. And based on this, constantly innovating to deliver quality sciencebacked technologies and treatments that meet their unmet needs and advance the field of aesthetic medicine. As a company, we are always looking to encourage open dialogue and listen to all perspectives. From connecting with thousands of consumers globally each year to understand their changing views, to listening to our customers and what they tell us about their patients’ motivations and needs. As the world around us evolves, we are driven by our mission to empower confidence in the patients and practitioners of today and tomorrow.

How does Allergan Aesthetics support practitioners and patients?

Everyone is different, and it’s important for us to understand the individual needs of the patients our customers serve. They are more than just a face or body, just like a practitioner is more than just an injector or a technician. And I see us as more than just a pharmaceutical company. By taking a 360° view, we look at all angles of the aesthetics journey to support practitioners and their patients at every step of the way. From the very first consultation to the moment a practitioner uses one of our products, we’re focused on being there to listen, enhance their skills and support them and their patients.

The Allergan Medical Institute (AMI) provides bespoke, quality educational programs to practitioners all around the world to help them hone their skills and pursue the highest levels of clinical excellence. Through various forums we aim to train over 75,000 practitioners globally every year. We offer expert-led training, online learning, and exclusive resources, so practitioners can confidently deliver outcomes that help their patients achieve their aesthetic goals.

Enhancing the patient-practitioner consultation is key. Through AMI and investment in consumer education we aim to support practitioners to navigate, communicate, and enhance this process to ensure patients are informed and empowered to confidently get the best out of their aesthetics journey.

The world is changing — how can you continue to meet the expectations of patients?

In recent years, we have seen a vast increase in consumer awareness and openness to aesthetics, combined with a rise in treatment options available. This means that expectations are naturally changing, and there is a need for us to better understand the evolving patient.

Last year we commissioned the Future of Aesthetics Global Trends Report to identify and understand the underlying social and cultural drivers and trends that are shaping the industry, so we can better prepare for the future.1 Our findings showed that people of all ethnicities, backgrounds and ages are seeking out aesthetic medicine, and that beauty is dropping the gender divide. Ultimately, people want to see themselves reflected and represented. By exploring these trends, we’re aiming to help practitioners understand how to connect, treat, and cater for the patient of tomorrow.

This in-depth understanding of patient needs also enables us to focus on what’s next. With science as our foundation, we continue to innovate to discover tomorrow’s therapies so that our diverse and comprehensive product portfolio can support individual patients’ aesthetics journey.

As the new VP of international marketing and commercial operations, what is your vision for the future of aesthetics?

The aesthetics industry is set to grow at a faster pace than ever before2 and we need to adapt and prepare for that. Our report only provided a glimpse of what’s to come, but it’s evident that inclusive beauty is the future, with gender and ethnicity no longer limiting aesthetic desires. For many, aesthetics is now part of everyday selfcare, a shift we are seeing all over the world. But we also know that people need to be informed and able to make aesthetics choices that are right for them. Education will therefore be central to the future of this industry.

As leaders in the industry, we also have a part to play in growing the aesthetics market responsibly. An important part of future proofing the industry is that as aesthetics treatments are medical procedures, it is driven by high ethical standards. This was a key finding in our report, that ethics is a priority for practitioners and patients. We hold ourselves to a high standard, and so do our customers, which is why ethics will be one of the topics we’re covering during our AMI symposia at AMWC this year.

Then finally, our company ethos is about the power of confidence: of shaping your own life, your own business, your own look. And so, when I think about a vision for the future, from an Allergan Aesthetics perspective, it will be continuing to focus on doing everything we can to help make that happen.

What are you excited about for the year ahead?

2022 was a busy year for Allergan Aesthetics. We reached the global milestone of shipping 100 million syringes of JUVÉDERM®, 3 which is a great source of pride for everyone at the company and demonstrates our dedication to patients and practitioners globally. We also launched HArmonyCa™, our first hybrid injectable, which is now available across many European markets as well as Latin America. This year, we will be building on these achievements and continuing to help our customers unlock their patient’s individuality with Allergan Aesthetics 360°, for all their practice, product, and patient needs. This year is set to be exciting!

Allergan Aesthetics will be at AMWC in Monaco this year. To unlock your patient’s individuality with Allergan Aesthetics 360° visit us on booth K2 and join our symposia ‘Discover your 360° with Allergan Aesthetics: Practice, Products, Purpose’ at 10.45AM on Thursday 30 March and ‘Unlocking your patient’s individuality with Allergan Aesthetics 360°’ at 9.45AM on 31 March, both in the Salles de Princes, Grimaldi Forum.

Disclaimers

This is a promotional material funded and developed by Allergan Aesthetics, an AbbVie company.

• Licence details and indications may vary between countries— Please consult individual product Directions for Use.

• HArmonyCa™ Lidocaine is referred to as HArmonyCa™ throughout. Common postoperative adverse events can include erythema, edema (swelling), pain, tenderness, and itching.

• Patients may experience potential side effects after treatment with Juvéderm® facial filler, which include: inflammatory reactions (redness, oedema, erythema, etc.), haematomas, induration or nodules, staining or discolourations at the injection site, etc.

• Adverse events should be reported to your local regulatory authority and Allergan Aesthetics office.

References

1. Allergan Aesthetics. The Future of Aesthetics Global Trends Report. May 2022. ALL-AGNA-220005.

2. Medical Insight. The Global Aesthetic Market Study: XIX. November 2021.

3. Allergan Aesthetics. Data on File. REF-96563